RxDoctor Payments Data

Stephanie Verderame, APRN

Gerontology · Rockford, ILNPI 1730856840

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (57.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Axsome Therapeutics, Inc. at 51.2% of the total. 2025 is the largest year on record at $12,090, more than ten times the $361 reported in 2021. Among gerontology clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$15,401in general payments, 2019–2025

Across 161 payments — averaging $95.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axsome Therapeutics, Inc.$8K
  • Impel Pharmaceuticals LLC$4K
  • AbbVie$1K
  • Biohaven Pharmaceutical Holding Company Ltd.$597
  • Pfizer$539
  • Lundbeck LLC$526
  • plus $1K from 10 others

What the payments were for

  • Speaking & faculty fees$8,90858%
  • Travel & lodging$1,99813%
  • Food & beverage$4,49529%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,401 in reported general payments places this provider in the 95th percentile of 180 gerontology providers in Illinois.

See all gerontology providers in Illinois

Medicare billing

Part B allowed, 2024
$11,914
Medicare patients
68
Services billed
269

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate61$107,158
UbrelvyUbrogepant81$99,867
Aimovig AutoinjectorErenumab-Aooe115$92,185
QuliptaAtogepant36$40,417
Emgality PenGalcanezumab-Gnlm45$33,058
Ajovy AutoinjectorFremanezumab-Vfrm21$20,063
Sumatriptan Succinate124$11,637
Duloxetine Hcl81$1,803
Gabapentin114$1,595
Propranolol Hcl ErPropranolol Hcl11$1,354
Orphenadrine Citrate ErOrphenadrine Citrate15$1,023
RizatriptanRizatriptan Benzoate121$965
Doxepin Hcl21$948
Nebivolol Hcl12$721
Zolpidem Tartrate ErZolpidem Tartrate15$646

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$1,008$140,284117 claims
PfizerNurtec Odt$539$107,15861 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 180 gerontology providers in Illinois.

Other gerontology in Rockford

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →